G-protein coupled receptor expression patterns delineate medulloblastoma subgroups

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Whittier, Kelsey L ^a   Boese, Erin A ^a   Gibson Corley, Katherine N ^a   Kirby, Patricia A ^a   Darbro, Benjamin W ^a   Qian, Qining ^a   Ingram, Wendy J ^c   Robertson, Thomas ^d   Remke, Marc ^e   Taylor, Michael D ^e   O'Dorisio, M Sue ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

G protein coupled receptors; Imaging targets; Medulloblastoma subgroups; Therapeutic targets

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

CEREBELLAR NEOPLASMS; CEREBELLUM; CLASSIFICATION; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC LINKAGE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; METABOLISM; PRESCHOOL CHILD;

CEREBELLAR NEOPLASMS; CEREBELLUM; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC LINKAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; MEDULLOBLASTOMA; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85048229342     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-66     Document Type: Article

References (64)

1. Louis DN, Ohgaki H, Wiestler OD: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114: 97-109. Doi 10.1007/s00401-007-0243-4 10.1007/s00401-007-0243-4
2. Mabbott DJ, Spiegler BJ, Greenberg ML, Rutka JT, Hyder DJ, Bouffet E: Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 2005, 23: 2256-2263. Doi: 10.1200/jco.2005.01.158 10.1200/JCO.2005.01.158
3. Watterson J, Simonton SC, Rorke LB, et al.: Fatal brain stem necrosis after standard posterior fossa radiation and aggressive chemotherapy for metastatic medulloblastoma. Cancer 1993, 71: 4111-4117. 10.1002/1097-0142(19930615)71:12<4111::AID-CNCR2820711250>3.0.CO;2-4
4. Ellison D: Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002, 28: 257-282. 10.1046/j.1365-2990.2002.00419.x
5. Kool M, Korshunov A, Remke M, et al.: Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012, 123: 473-484. Doi 10.1007/s00401-012-0958-8 10.1007/s00401-012-0958-8
6. Northcott PA, Dubuc AM, Pfister S, Taylor MD: Molecular subgroups of medulloblastoma. Expert Rev Neurotherapeutics 2012, 12: 871-884. Doi 10.1586/ern.12.66 10.1586/ern.12.66
7. Taylor MD, Northcott PA, Korshunov A, et al.: Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123: 465-472. Doi 10.1007/s00401-011-0922-z 10.1007/s00401-011-0922-z
8. Cho YJ, Tsherniak A, Tamayo P, et al.: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011, 29: 1424-1430. Doi 10.1200/jco.2010.28.5148 10.1200/JCO.2010.28.5148
9. Kool M, Koster J, Bunt J, et al.: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008, 3: e3088. Doi 10.1371/journal.pone.0003088 10.1371/journal.pone.0003088
10. Northcott PA, Korshunov A, Witt H, et al.: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011, 29: 1408-1414. Doi 10.1200/jco.2009.27.4324 10.1200/JCO.2009.27.4324
11. Remke M, Hielscher T, Korshunov A, et al.: FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011, 29: 3852-3861. Doi 10.1200/jco.2011.36.2798 10.1200/JCO.2011.36.2798
12. Remke M, Hielscher T, Northcott PA, et al.: Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011, 29: 2717-2723. Doi 10.1200/jco.2011.34.9373 10.1200/JCO.2011.34.9373
13. Thompson MC, Fuller C, Hogg TL, et al.: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24: 1924-1931. Doi 10.1200/jco.2005.04.4974 10.1200/JCO.2005.04.4974
14. Northcott PA, Jones DT, Kool M, et al.: Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012, 12: 818-834. Doi 10.1038/nrc3410 10.1038/nrc3410
15. Northcott PA, Nakahara Y, Wu X, et al.: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009, 41: 465-472. Doi 10.1038/ng.336 10.1038/ng.336
16. Parsons DW, Li M, Zhang X, et al.: The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331: 435-439. Doi 10.1126/science.1198056 10.1126/science.1198056
17. Gibson P, Tong Y, Robinson G, et al.: Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468: 1095-1099. Doi 10.1038/nature09587 10.1038/nature09587
18. Gilbertson RJ, Ellison DW: The origins of medulloblastoma subtypes. Annu Rev Pathol 2008, 3: 341-365. Doi 10.1146/annurev.pathmechdis.3.121806.151518 10.1146/annurev.pathmechdis.3.121806.151518
19. Northcott PA, Korshunov A, Pfister SM, Taylor MD: The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012, 8: 340-351. Doi 10.1038/nrneurol.2012.78 10.1038/nrneurol.2012.78
20. Robarge KD, Brunton SA, Castanedo GM: GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009, 19: 5576-5581. Doi 10.1016/j.bmcl.2009.08.049 10.1016/j.bmcl.2009.08.049
21. Rudin CM, Hann CL, Laterra J, et al.: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361: 1173-1178. Doi 10.1056/NEJMoa0902903
22. Wu J, Xie N, Zhao X, Nice EC, Huang C: Dissection of aberrant GPCR signaling in tumorigenesis-a systems biology approach. Cancer Genomics Proteomics 2012, 9: 37-50.
23. Marti-Solano M, Guixa-Gonzalez R, Sanz F, Pastor M, Selent J: Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design. Curr Pharm Des 2013.
24. Khanna G, Bushnell D, O'Dorisio MS: Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist 2008, 13: 382-389. Doi 13/4/382 10.1634/theoncologist.2007-0175
25. Khanna G, O'Dorisio MS, Menda Y, et al.: Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer 2008, 50: 561-566. Doi 10.1002/pbc.21194 10.1002/pbc.21194
26. Beutler D, Avoledo P, Reubi JC: Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 2005, 103: 869-873. Doi 10.1002/cncr.20822 10.1002/cncr.20822
27. Menda Y, O'Dorisio MS, Kao S, et al.: Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010, 51: 1524-1531. Doi jnumed.110.075226 10.2967/jnumed.110.075226
28. O'Dorisio MS, Khanna G, Bushnell D: Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children. Cancer Metastasis Rev 2008, 27: 665-677. Doi 10.1007/s10555-008-9153-8 10.1007/s10555-008-9153-8
29. Fredriksson R, Schioth HB: The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 2005, 67: 1414-1425. Doi 10.1124/mol.104.009001 10.1124/mol.104.009001
30. Maurel B, Le Digarcher A, Dantec C, Journot L: Genome-wide profiling of G protein-coupled receptors in cerebellar granule neurons using high-throughput, real-time PCR. BMC Genomics 2011, 12: 241. Doi 10.1186/1471-2164-12-241 10.1186/1471-2164-12-241
31. Mestdagh P, Van Vlierberghe P, De Weer A, et al.: A novel and universal method for microRNA RT-qPCR data normalization. Genome biology 2009, 10: R64. Doi 10.1186/gb-2009-10-6-r64 10.1186/gb-2009-10-6-r64
32. Ellison DW, Dalton J, Kocak M, et al.: Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011, 121: 381-396. Doi 10.1007/s00401-011-0800-8 10.1007/s00401-011-0800-8
33. Jung B, Ahmad N: Melatonin in cancer management: progress and promise. Cancer Res 2006, 66: 9789-9793. Doi 10.1158/0008-5472.can-06-1776 10.1158/0008-5472.CAN-06-1776
34. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005,310(5753):1504-1510. 10.1126/science.1116221
35. Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003, 95: 1440-1452. 10.1093/jnci/djg058
36. Remke M, Hering E, Gerber NU, et al.: Somatostatin receptor subtype 2 (sst) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst 2013. Doi 10.1007/s00381-013-2142-4
37. Fruhwald MC, O'Dorisio MS, Pietsch T, Reubi JC: High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res 1999, 45: 697-708.
38. Fruhwald MC, Rickert CH, O'Dorisio MS: Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res 2004, 10: 2997-3006. 10.1158/1078-0432.CCR-03-0083
39. Innamorati G, Valenti M, Giovinazzo F, Carbonare L, Parenti M, Bassi C: Molecular approaches to target GPCRs in cancer therapy. Pharmaceuticals 2011, 4: 567-589. Doi 10.3390/ph4040567 10.3390/ph4040567
40. Bajetta E, Catena L, Valente M, Bianco N, Bellomo F, Bombardieri E: New perspectives in the treatment of neuroendocrine tumours. Anticancer Res 2012, 32: 4193-4200.
41. Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, Yamazaki H: Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 2013, 33: 747-754.
42. Carmon KS, Lin Q, Gong X, Thomas A, Liu Q: LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/beta-catenin signaling. Mol Cell Biol 2012, 32: 2054-2064. Doi 10.1128/mcb.00272-12 10.1128/MCB.00272-12
43. Al-Kharusi MR, Smartt HJ, Greenhough A, et al.: LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis 2013, 34: 1150-1157. Doi 10.1093/carcin/bgt020 10.1093/carcin/bgt020
44. Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP: Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 2012, 30: 2378-2386. Doi 10.1002/stem.1233 10.1002/stem.1233
45. Carmon KS, Gong X, Lin Q, Thomas A, Liu Q: R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci USA 2011, 108: 11452-11457. Doi 10.1073/pnas.1106083108 10.1073/pnas.1106083108
46. de Lau WB, Snel B, Clevers HC: The R-spondin protein family. Genome biology 2012, 13: 242. Doi 10.1186/gb-2012-13-3-242 10.1186/gb-2012-13-3-242
47. Banks WA: Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 2009,9(Suppl 1):S3. Doi 10.1186/1471-2377-9-s1-s3 10.1186/1471-2377-9-S1-S3
48. Seelig A: The role of size and charge for blood-brain barrier permeation of drugs and fatty acids. J Mol Neurosci 2007, 33: 32-41. 10.1007/s12031-007-0055-y
49. Richter GH, Fasan A, Hauer K, et al.: G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J Pathol 2013, 230: 70-81. Doi 10.1002/path.4170 10.1002/path.4170
50. Fulton AM, Ma X, Kundu N: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006, 66: 9794-9797. Doi 10.1158/0008-5472.can-06-2067 10.1158/0008-5472.CAN-06-2067
51. Loh JK, Hwang SL, Lieu AS, Huang TY, Howng SL: The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal. J Neurooncol 2002, 57: 147-150. 10.1023/A:1015782809966
52. Wang D, Dubois RN: Prostaglandins and cancer. Gut 2006, 55: 115-122. Doi 10.1136/gut.2004.047100 10.1136/gut.2004.047100
53. Baryawno N, Sveinbjornsson B, Eksborg S, et al.: Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-oncology 2008, 10: 661-674. Doi 10.1215/15228517-2008-035 10.1215/15228517-2008-035
54. Boyd MJ, Berthelette C, Chiasson JF: A novel series of potent and selective EP(4) receptor ligands: facile modulation of agonism and antagonism. Bioorg Med Chem Lett 2011, 21: 484-487. Doi 10.1016/j.bmcl.2010.10.106 10.1016/j.bmcl.2010.10.106
55. Goessling W, North TE, Loewer S, et al.: Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009, 136: 1136-1147. Doi 10.1016/j.cell.2009.01.015 10.1016/j.cell.2009.01.015
56. Katoh Y, Katoh M: Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009, 9: 873-886. 10.2174/156652409789105570
57. Martin V, Herrera F, Carrera-Gonzalez P, et al.: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006, 66: 1081-1088. Doi 10.1158/0008-5472.can-05-2354 10.1158/0008-5472.CAN-05-2354
58. Vijaya L, Thomas CR Jr, Reiter RJ, Herman TS, et al.: Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002, 20: 2575-2601. 10.1200/JCO.2002.11.004
59. Nakamura E, Kozaki K, Tsuda H, et al.: Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008, 99: 1390-1400. Doi 10.1111/j.1349-7006.2008.00838.x 10.1111/j.1349-7006.2008.00838.x
60. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM: MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002, 192: 147-156. 10.1016/S0303-7207(02)00029-1
61. Tam CW, Chan KW, Liu VW, Pang B, Yao KM, Shiu SY: Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 2008, 45: 403-412. Doi 10.1111/j.1600-079X.2008.00608.x 10.1111/j.1600-079X.2008.00608.x
62. Merighi S, Simioni C, Gessi S, et al.: A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 2009, 11: 1064-1073.
63. Saito M, Yaguchi T, Yasuda Y, Nakano T, Nishizaki T: Adenosine suppresses CW2 human colonic cancer growth by inducing apoptosis via A(1) adenosine receptors. Cancer Lett 2010, 290: 211-215. Doi 10.1016/j.canlet.2009.09.011 10.1016/j.canlet.2009.09.011
64. Fishman P, Bar-Yehuda S, Synowitz M, et al.: Adenosine receptors and cancer. Handbook Exp Pharmacol 2009, 399-441. Doi 10.1007/978-3-540-89615-9_14